These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Fulminant hepatic failure associated with benzbromarone treatment: a case report. Arai M; Yokosuka O; Fujiwara K; Kojima H; Kanda T; Hirasawa H; Saisho H J Gastroenterol Hepatol; 2002 May; 17(5):625-6. PubMed ID: 12084041 [No Abstract] [Full Text] [Related]
5. Autoimmune hepatitis following drug-induced liver injury in an elderly patient. Kumagai J; Kanda T; Yasui S; Haga Y; Sasaki R; Nakamura M; Wu S; Nakamoto S; Arai M; Iino Y; Yokosuka O Clin J Gastroenterol; 2016 Jun; 9(3):156-9. PubMed ID: 27170297 [TBL] [Abstract][Full Text] [Related]
6. Implementation Status of Liver Function Tests for Monitoring Benzbromarone-Induced Hepatotoxicity: An Epidemiological Survey Using the Japanese Claims Database. Imai S; Nasuhara Y; Momo K; Oki H; Kashiwagi H; Sato Y; Miyai T; Sugawara M; Takekuma Y Biol Pharm Bull; 2021; 44(10):1499-1505. PubMed ID: 34602558 [TBL] [Abstract][Full Text] [Related]
8. Benzbromarone as a possible cause of acute kidney injury in patients with urolithiasis: Two case reports. Ye X; Wu J; Tang K; Li W; Xiong C; Zhuo L Medicine (Baltimore); 2019 Apr; 98(15):e15214. PubMed ID: 30985721 [TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and safety of benzbromarone in elderly hypertensive patients with hyperuricemia. Gao H Pak J Pharm Sci; 2019 Jul; 32(4(Supplementary)):1869-1871. PubMed ID: 31680085 [TBL] [Abstract][Full Text] [Related]
15. Hepatic injury caused by benzbromarone. van der Klauw MM; Houtman PM; Stricker BH; Spoelstra P J Hepatol; 1994 Mar; 20(3):376-9. PubMed ID: 8014449 [TBL] [Abstract][Full Text] [Related]
16. The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand. Stamp LK; Haslett J; Frampton C; White D; Gardner D; Stebbings S; Taylor G; Grainger R; Kumar R; Kumar S; Kain T; Porter D; Corkill M; Cathro A; Metcalfe S; Wyeth J; Dalbeth N Intern Med J; 2016 Sep; 46(9):1075-80. PubMed ID: 27391386 [TBL] [Abstract][Full Text] [Related]
17. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127 [TBL] [Abstract][Full Text] [Related]
18. [Drug-induced hepatic injury, the challenge for cause investigation]. Matsumoto K Rinsho Byori; 2011 Dec; 59(12):1117-22. PubMed ID: 22338914 [TBL] [Abstract][Full Text] [Related]
19. Inactivation of CYP3A4 by Benzbromarone in Human Liver Microsomes. Masubuchi Y; Kondo S Drug Metab Lett; 2016; 10(1):16-21. PubMed ID: 26693855 [TBL] [Abstract][Full Text] [Related]
20. Metabolic Epoxidation Is a Critical Step for the Development of Benzbromarone-Induced Hepatotoxicity. Wang H; Peng Y; Zhang T; Lan Q; Zhao H; Wang W; Zhao Y; Wang X; Pang J; Wang S; Zheng J Drug Metab Dispos; 2017 Dec; 45(12):1354-1363. PubMed ID: 29021351 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]